(Q36353291)

13 August 2017

Evaluating the value of number of cycles of docetaxel and prednisone in men with metastatic castration-resistant prostate cancer (English)

1 reference

13 August 2017

1 reference

1 reference

9

Ian F Tannock

1 reference

13 August 2017

Gregory R Pond

1

1 reference

13 August 2017

Andrew J Armstrong

2

1 reference

13 August 2017

Brian A Wood

3

1 reference

13 August 2017

Melissa Brookes

4

1 reference

13 August 2017

Lance Leopold

5

1 reference

13 August 2017

William R Berry

6

1 reference

13 August 2017

Ronald de Wit

7

1 reference

13 August 2017

Mario A Eisenberger

8

1 reference

13 August 2017

Guru Sonpavde

10

1 reference

13 August 2017

language of work or name

English

0 references

publication date

22 June 2011

1 reference

13 August 2017

1 reference

13 August 2017

61

1 reference

13 August 2017

2

1 reference

13 August 2017

363-369

1 reference

Randomized, double-blind, placebo-controlled phase III trial comparing docetaxel and prednisone with or without bevacizumab in men with metastatic castration-resistant prostate cancer: CALGB 90401.

13 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Abiraterone and increased survival in metastatic prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study.

30 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

The development of risk groups in men with metastatic castration-resistant prostate cancer based on risk factors for PSA decline and survival

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Phase III study of immediate compared with delayed docetaxel after front-line therapy with gemcitabine plus carboplatin in advanced non-small-cell lung cancer

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study

22 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3483076

Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer

22 September 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21715086

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21715086

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Randomized phase II trial of docetaxel plus prednisone in combination with placebo or AT-101, an oral small molecule Bcl-2 family antagonist, as first-line therapy for metastatic castration-resistant prostate cancer

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/21715086

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1016/J.EURURO.2011.06.034

1 reference

13 August 2017

1 reference

13 August 2017

PubMed publication ID

21715086

1 reference